Immunology / Virology & Vaccines

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #mRNA #Vaccines

New study provides global analysis of Covid-19 vaccines

A new study by Novateur Ventures provides a comparative analysis of twelve Covid-19 vaccines that had initiated or announced the Phase III clinical trial stage by early November 2020. The study highlights the early successes, as well as the hurdles and barriers yet to be overcome for ending the global… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Vaccines

Moderna’s Covid-19 vaccine antibody persistence data published

Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, has had antibody persistence data out to six months following the second Covid-19 vaccine dose published in The New England Journal of Medicine. “We are pleased that this new data shows antibody persistence through six months following the second dose… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines #Vaccines

Valneva reports positive Phase I/II data for Covid-19 vaccine

Valneva, a specialty vaccine company focused on the development and commercialisation of prophylactic vaccines for infectious diseases with significant unmet medical need, has announced positive data for Part A of the Phase I/II clinical trial of its inactivated, adjuvanted Covid-19 vaccine candidate, VLA2001. Based on this data, the company plans… Read More

#Covid-19 #News

#Clinical trial #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Novavax initiates Covid-19 vaccine clinical trial crossover

Biotech company Novavax has announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company’s Covid-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax’ Phase IIb trial in South Africa and its pivotal Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

T cells
#Antibodies #Covid-19 #Immunology / Virology & Vaccines #Online focus #Vaccines

T Cells recognise recent SARS-CoV-2 variants

When variants of SARS-CoV-2 emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the… Read More

#Covid-19 #News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Life sciences #Narrated podcasts

Vaccine innovation in the age of Covid-19

This is the latest episode of the free DDW podcast, titled Vaccine innovation in the age of Covid-19. It covers two narrated articles written for DDW and read aloud by Megan Thomas. These articles are titled: “Vaccine innovation in the age of Covid-19 & beyond” and “Creating vaccines: Why we… Read More

#Podcasts

#Covid-19 #Immunology / Virology & Vaccines #Podcast #Research

Vaccine innovation in the age of Covid-19 – podcast

The latest free to listen to DDW podcast episode, Vaccine innovation in the age of Covid-19, covers two articles written for DDW and read aloud by DDW Editorial Assistant, Megan Thomas. These articles are titled: “Vaccine innovation in the age of Covid-19 & beyond” and “Creating vaccines: Why we should… Read More

#News

#Biotherapeutics #Drug development #Immunology / Virology & Vaccines #Vaccines

ENPICOM accelerates antibody and vaccine discovery

Viroclinics-DDL, a Contract Research Organisation (CRO) specialising in molecular diagnostic testing and assay development, and ENPICOM, a bioinformatics software engineering company, have announced the approval of a joint MIT Zuid subsidy (SME Innovation Stimulation Top Sectors South Holland) application. This R&D partnership project combines in vitro diagnostic and high-throughput sequencing… Read More

#News

#Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Vaccines

GSK to support manufacture of Novavax’ Covid-19 vaccine

Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ Covid-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide… Read More

#Covid-19 #News

#Covid-19 #Drug development #Immunology / Virology & Vaccines #Research

Modelling and simulation facilitates drug repurposing to counter Covid-19

By Dr Craig R. Rayner, FRCP Edin, PharmD, MBA, President, Integrated Drug Development at Certara Right at the start of the Covid-19 pandemic, medical researchers began questioning whether there were any existing, on-market drugs that might prove effective against SARS-CoV-2. They wanted to offer healthcare professionals and patients some known… Read More

#Business & Investment #Exclusive Content #News

#Biotechnology #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Pharma #Vaccines

The effect of Covid-19 solutions on the clinical trials process

Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases at ICON, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership. The world responded to the Covid-19 crisis at unprecedented speed — including vaccine development. During a pandemic, timing… Read More

#Business & Investment #Covid-19 #Exclusive Content #News

#Cancer research #Covid-19 #Immunology / Virology & Vaccines #Research

Cancer drug lessens toxicity of protein from virus that causes Covid-19

The University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-COV-2 and then used an FDA-approved cancer drug to blunt the viral protein’s detrimental effects. In experiments in fruit flies and human cell lines, the team discovered the cell process that the virus… Read More

#Cancer Research #Covid-19 #News

#AstraZeneca #Clinical trial #Covid-19 #Immunology / Virology & Vaccines

Oxford-AstraZeneca US vaccine trial data may be outdated

The Data and Safety Monitoring Board (DSMB) has notified the National Institute of Allergy and Infectious Diseases (NIAID), Biomedical Advanced Research and Development Authority (BARDA), and AstraZeneca that it is “concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial”. Trial volunteers received two standard… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AstraZeneca #Covid-19 #Drug delivery #Immunology / Virology & Vaccines

US trial data show Oxford-AstraZeneca vaccine is safe and 79% effective 

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca in the US, Chile and Peru has shown that the vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom. In the trial, which… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AstraZeneca #Biotechnology #Covid-19 #Immunology / Virology & Vaccines #Pfizer

Existing vaccines may protect against coronavirus variants

Scientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise or stop infection from variants that are circulating in South Africa, Brazil and elsewhere. The data suggests that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly,… Read More

#Covid-19 #News